Neurocrine Biosciences | NBIX - Assets


Neurocrine Biosciences reported $5.63B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Cytokinetics USD 1.82B 99.77M Sep/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Exelixis USD 2.51B 19.26M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Prothena USD 283.52M 19.06M Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Repligen USD 2.93B 23.77M Sep/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Teva Pharmaceutical Industries USD 40.04B 185M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026